FUTURE OF HEALTHCARE, MEDICAL DEVICES
Novateur Ventures | December 13, 2022
Novateur Ventures, a leading global life sciences advisory firm and Biotechnology Innovation Organization the world's largest advocacy association for biosciences, research and academic institutions, launched an industry networking information app, Event Guide to JPM 2023, which provides listings for an anticipated >200 satellite networking events taking place during the 41st Annual J.P. Morgan Health Care Conference on January 9-12, 2023, in San Francisco, CA.
The Event Guide to JPM 2023 app, developed by Novateur Ventures and co-managed by BIO, features event search and filter capabilities, provides links to event and registration information, and in the case of in-person events, loads mapping software for directions to the event. Organizations can also use the app to list their scheduled events being held during the conference timeframe.
"It was important for me to develop an app that allowed life science professionals to make important industry connections because, over my career, some of the most transformational relationships I have developed are the direct result of industry networking events. Novateur is delighted to be collaborating with BIO, to give the app a global reach,"
Ali Ardakani, Founder and Managing Director of Novateur Ventures
“I see the app as a natural addition to BIO Partnering at JPM Week. We’re always working to help the industry partner more easily and effectively, and I’m excited to bring the whole JPM Week networking landscape to the palm of your hand. We are excited to be partnering with Novateur on managing and launching this app,” says Mackensie Vernetti, BIO’s Director of Partnering Operations.
About Novateur Ventures
Novateur Ventures is an established life sciences advisory and investment firm with extensive experience in business development and product development of therapeutics, medical devices, and digital health products.
About Biotechnology Innovation Organization
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Good Day BIO is the only daily newsletter at the intersection of biotech, politics and policy. Subscribe here.
FUTURE OF HEALTHCARE,MEDICAL DEVICES
Capterra | November 30, 2022
The rising adoption of connected medical devices is accelerating cyberattacks, according to Capterra’s new Medical IoT Survey of healthcare IT professionals. The survey also reveals that 67% of healthcare cyberattacks impact patient data and nearly half impact patient care, an indication that rising security risks in the industry are leading to severe consequences in patient outcomes and privacy.
The medical internet of things is helping to make healthcare more convenient, efficient, and patient-centric. However, connected devices with IoT sensors often have unprotected security vulnerabilities that endanger healthcare facilities, and even patients. In fact, medical practices with more than 70% of their devices connected are 24% more likely to experience a cyberattack than practices with 50% or fewer connected devices.
“As a healthcare organization connects more medical devices to its network, its attack surface expands. Connected medical devices often go unmonitored for security vulnerabilities, and because they run on a wide array of software and hardware platforms, it’s difficult to monitor with a single tool. This means that many connected medical devices are left wide open to cyberattacks.”
Zach Capers, senior security analyst at Capterra
More than half of healthcare IT staff rate the cybersecurity threat level in the industry as high or extreme, yet many healthcare organizations are not taking the necessary steps to protect medical IoT devices. Alarmingly, 57% do not always change the default username and password for each new connected medical device that is put into use. Additionally, 82% run connected medical devices on old Windows systems.
If a security vulnerability is discovered, organizations should patch the device or update its firmware as soon as possible. Unfortunately, 68% of healthcare organizations don’t always update connected devices when a patch is available. However, vulnerabilities and associated patches aren’t always well publicized, which means healthcare IT staff must stay up-to-date on emerging threats to medical IoT devices.
Medical IoT security requires proactive and ongoing vigilance. Healthcare practices should conduct routine vulnerability assessments before connecting medical devices to their IT network. They should also keep an up-to-date and accurate inventory of all connected devices plus associated software and firmware, and use software to monitor these devices.
Read the full report on Capterra.com to learn more about best practices for healthcare organizations to strengthen security for their medical IoT devices.
Capterra is the leading software reviews and selection platform that connects businesses to the right technology. Compare software, read and leave reviews, and access objective insights that empower business growth.
Florence Healthcare | November 18, 2022
Florence Healthcare™, a clinical research technology company headquartered in Atlanta, Georgia, announced the completion of a year-long third-party study on the impact of Site Enablement Platforms™ on clinical research timelines and costs.
The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor portals and new Site Enablement Platforms on research sponsor and Contract Research Organization study timelines and budgets.
“Pharma sponsors and CROs realize the importance of enabling sites to do their best work - but only recently have they discovered that traditional site portals are more hindrance than help. Yet, these organizations weren't able to measure the true impact of switching to a Site Enablement Platform. This year-long study aimed to fix that and highlight how linking fragmented workflows accelerates the full lifecycle of clinical trials.”
Ryan Jones, CEO of Florence Healthcare
Site enablement is a new technology category that prioritizes the needs of the site, a major shift from past technology that only looked at the experience of the sponsor. These platforms, including Florence Healthcare’s SiteLink™, insist on ease-of-use and ease-of-setup for the site, quality support, and simplified integrations. SiteLink works in conjunction with eBinders™, an electronic Investigator Site File solution used by over 12,000 research sites in 45 countries.
About the Study
Marketcap Consulting conducted interviews with clinical research operations leaders harnessing SiteLink, examined timelines and study costs, and analyzed the impact across the sites in the study. On average, the team found that SiteLink accelerated study start-up by four weeks and study close-out by two weeks at every site. For a 50-site study, this six-week acceleration reduced cash burn by one million dollars.
“We can see a clear positive impact on study timelines and cash burn when research sponsors and CROs implement Site Enablement Platforms,” said Joel White, founder of Marketcap Consulting. “This early study reveals that by enabling sites to do their best work, the clinical research industry unlocks value across the full research cycle.”
“While the financial impact of switching to SiteLink makes investing in site enablement an easy choice for sponsors and CROs, it’s really the acceleration of studies that gets our team at Florence Healthcare excited,” said Jones. “We aim to double the output of research teams by the end of the decade, and enabling sites is the way to do it.”
About Florence Healthcare
Florence Healthcare’s clinical trial software helps more than 12,000 research sites in 45 countries manage their documents, data, and workflows. The Florence Healthcare™ platform also provides remote access so sponsors and Contract Research Organizations can collaborate with their sites around the world. Florence Healthcare users now perform 5.8 million remote monitoring activities each month.
FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE
MVIS® Global Bionic Healthcare ESG Index | December 08, 2022
MarketVector IndexesTM announced the licensing of the MVIS® Global Bionic Healthcare ESG Index to underlie the VanEck Bionic Engineering UCITS ETF.
The MVIS® Global Bionic Healthcare ESG Index includes companies that generate at least 50% of their revenue from medical, dental, or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue.
“We have observed sound growth in the global bionics market which includes a range of niche healthcare solutions from medical implants to prostheses and bioprinting. These innovations in medical technology open new horizons to meet the rising needs of an aging population, significantly improve the quality of life for people with disabilities, and pave the way for the discovery of potentially life-saving treatments. The MVIS® Global Bionic Healthcare ESG Index offers an investable benchmark to track the leading companies in this industry.”
Mirela Stefanova, Manager of Equity Operations at MarketVector
The MVIS® Global Bionic Healthcare ESG Index is weighted by free float market capitalization and reviewed on a quarterly basis. The index is calculated in USD as a price index and a total return net index. Capping factors are applied to avoid overweighting of single index components.
“The proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,” says Martijn Rozemuller, CEO at VanEck Europe. “At the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.”
About MarketVector Indexes
MarketVector IndexesTM is a regulated Benchmark Administrator in Europe, incorporated in Germany and registered with the Federal Financial Supervisory Authority (BaFin). MarketVector maintains indexes under the MarketVectorTM, MVIS® and BlueStar® names. With a mission to accelerate index innovation globally, MarketVector is best known for its broad suite of Thematic indexes, a long-running expertise in Hard Asset-linked Equity indexes, and its pioneering Digital Asset index family. MarketVector is proud to be in partnership with more than 25 Exchange Traded Product issuers and index fund managers in markets throughout the world, with approximately USD 26.99 billion in assets under management.